Inventiva S.A. (IVA)
NASDAQ: IVA · Real-Time Price · USD
2.600
-0.080 (-2.99%)
Dec 3, 2024, 1:30 PM EST - Market open
Inventiva Employees
As of December 31, 2023, Inventiva had 123 total employees, including 120 full-time and 3 part-time employees. The number of employees increased by 10 or 8.85% compared to the previous year.
Employees
123
Change (1Y)
10
Growth (1Y)
8.85%
Revenue / Employee
$167,907
Profits / Employee
-$907,576
Market Cap
217.49M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Accuray | 987 |
Amarin Corporation | 275 |
Inhibrx Biosciences | 172 |
Caribou Biosciences | 158 |
Nkarta | 150 |
Nektar Therapeutics | 137 |
XBiotech | 82 |
Trevi Therapeutics | 25 |
IVA News
- 11 days ago - Inventiva reports 2024 Third Quarter Financial Information¹ - GlobeNewsWire
- 12 days ago - Combined General Meeting of December 11, 2024 - Availability of the preparatory documents - GlobeNewsWire
- 15 days ago - Alight to Enhance the Employee Experience with Launch of Alight Worklife® on Microsoft Teams - Business Wire
- 17 days ago - Inventiva will present data from the final analysis of the Phase 2 study evaluating the combination of lanifibranor with empagliflozin in patients with MASH and T2D at the AASLD The Liver Meeting® late-breaker session - GlobeNewsWire
- 4 weeks ago - Inventiva announces the positive recommendation of the fifth DMC of the NATiV3 Phase 3 clinical trial with lanifibranor in patients with MASH - GlobeNewsWire
- 6 weeks ago - Inventiva announces a late breaker abstract from LEGEND, Phase 2 trial, evaluating lanifibranor in combination with empagliflozin in MASH at the AASLD The Liver Meeting® 2024 - GlobeNewsWire
- 7 weeks ago - Inventiva announces the availability of a prospectus in connection with its financing through the issuance of ordinary shares and pre-funded warrants - GlobeNewsWire
- 7 weeks ago - Why Is Fatty-Liver Drug Developer Inventiva Stock Trading Higher On Monday? - Benzinga